16 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
32324396	17	p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators.	China Pharmaceutical University
32832028	47	Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.	Genentech
32832022	33	Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors.	Merck
32551006	134	Discovery of an Atropisomeric PI3K? Selective Inhibitor through Optimization of the Hinge Binding Motif.	Gilead Sciences
32035698	40	Discovery and SAR of aryl hydroxy pyrimidinones as potent small molecule agonists of the GPCR APJ.	Bristol-Myers Squibb Research and Development
27366941	44	Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.	Vertex Pharmaceuticals
31749906	52	Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy.	Merck
31246024	106	Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.	Bristol-Myers Squibb Research & Development
32297743	59	Discovery of (2	Astrazeneca
31851518	61	The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-	Astrazeneca
30500190	36	Design and Optimization of Sulfone Pyrrolidine Sulfonamide Antagonists of Transient Receptor Potential Vanilloid-4 with in Vivo Activity in a Pulmonary Edema Model.	TBA
30929436	88	Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.	TBA
32184970	55	Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation.	Gilead Sciences
30638874	64	Discovery of new indole-based acylsulfonamide Na	Bristol-Myers Squibb Research and Development